Natural killer (NK) cells are innate immune effector cells with potent cytotoxicity; thus, they can eliminate abnormal cells, such as tumor cells and virally infected cells. CAR-NK cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies, based on using NK cells. In comparison to CAR-T therapy, CAR-NK cell therapy represents a safer alternative with a lower chance of cytokine release syndrome and graft-versus-host disease, more efficient antitumor activity, and higher efficiency for off-the-shelf production.
To ensure the safety and quality of CAR-NK cells, the whole production process of CAR-NK cells, including NK cell collection, CAR development, and CAR-NK cell preparation, requires strict control and high-quality reagents. We will address obstacles related to the production of CAR-NK cells and provide solutions to improving their development process.
In this webinar, Dr. Huo Tong will discuss the barriers associated with CAR-NK cell production and provide solutions to improve their development process.
• Brief introduction on the CAR-NK cell production process.
• CAR-NK success determining factors: scFv, antibody, cytokine, etc.
• Problems and solutions in production stage.
About the speaker
Dr. Tong Huo is the Associate Product Manager at Sino Biological. He is in charge of the protein product strategy, including product marketing, product development, and product line optimization. Before joining Sino Biological, Dr. Huo obtained his Ph.D. degree in Biochemistry and Molecular Biology from Nankai University, China. After graduation, he did his post-doctoral training and worked as a Research Scientist at the Baylor College of Medicine in Houston, Texas. Dr. Huo’s fields of expertise include protein science, structural biology, and drug discovery. He has published featured papers in high-impact journals such as JACS, Protein & Cell and JMC, and more.